
|Articles|April 1, 2004
Anti-TNF-? formula enhances wound healing
Washington - Topical application of anti-tumor necrosis factor-? (TNF-?) monoclonal antibody (infliximab) produced dramatic improvement with wound closure in chronic, non-healing leg ulcers, said Markus Streit, M.D., department of dermatology, Inselspital, Bern, Switzerland.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Transformative Advances This Year and Beyond
2
FDA Proposes Expansion of US Sunscreen Ingredient Standards with Bemotrizinol
3
Phase 3b Study Confirms Ligelizumab’s Consistent CSU Control
4
Global Hidradenitis Suppurativa Atlas (GHiSA) Finds HS Affects 1% of the World's Population
5


















